Whether beta-blockers reduce atrial arrhythmias and, when added to an angiotensinconverting enzyme (ACE) inhibitor, ventricular arrhythmia is unknown. BACKGROUND Ventricular and atrial arrhythmias are common after acute myocardial infarction (AMI) and are associated with a poor prognosis. Angiotensin-converting enzyme inhibitors reduce the incidence of both types of arrhythmia.
Cardiac arrhythmias are common early after myocardial infarction (MI) and portend a poor prognosis (1) (2) (3) (4) . Elevated sympathetic nervous system activity is one contributory mechanism and, by counteracting this, beta-adrenoceptor antagonists may reduce cardiac electrical instability (5) (6) (7) (8) . Most
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attention has been paid to ventricular arrhythmias, and these were the focus of previous studies of the antiarrhythmic action of beta-blockers after MI (9 -13) . It is also recognized, however, that atrial fibrillation (AF) results in a worse outcome after MI, although no placebo-controlled trial has examined whether beta-blockers reduce the risk of atrial arrhythmias in this setting (2,4,14 -17) .
More recently, angiotensin-converting enzyme (ACE) inhibitors have been shown to reduce both ventricular and atrial arrhythmias in higher risk post-MI patients (18 -21) . It is not known whether beta-blockers, added to ACE inhibitor treatment, will further reduce arrhythmias in these patients.
The Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) study was a multinational prospective, randomized, event-driven, mortality/ morbidity trial carried out in patients with recent acute MI and left ventricular systolic dysfunction (22, 23) . All patients were expected to be treated with an ACE inhibitor (and 98% were). Patients were blindly allocated to placebo or carvedilol. This analysis describes the effect of carvedilol on the risk of atrial and ventricular arrhythmias.
METHODS
The CAPRICORN trial. The design and primary results of the CAPRICORN trial have been described in detail elsewhere (22, 23) . Briefly, 984 patients were allocated to placebo and 975 were allocated to carvedilol between 3 to 21 days post-MI (mean 10 days) and followed for an average of 1.3 years. All prespecified end points (death and certain types of cardiovascular hospitalization) were adjudicated by a blinded end point committee. Arrhythmia analysis. Cardiac arrhythmias were not a prespecified end point in the CAPRICORN trial. This analysis was, therefore, a post-hoc, though blinded, one. One end point committee member (J.M.) reviewed all adverse and serious adverse event reports (AEs and SAEs) without knowing treatment allocation. All events thought to be related to an arrhythmia were assigned to one of the following categories, which were decided upon before the analysis was undertaken:
Atrial arrhythmias: 1) any report of supraventricular ectopic beats, atrial tachycardia, atrial flutter, AF, or any other "supraventricular tachycardia," excluding sinus tachycardia; 2) AF/atrial flutter only. Ventricular arrhythmias: 1) any report of ventricular ectopic beats, ventricular tachycardia, ventricular fibrillation, or ventricular flutter; 2) "malignant" ventricular arrhythmias only (i.e., ventricular tachycardia, ventricular fibrillation, and ventricular flutter).
Arrhythmias were identified and characterized according to the AE narrative, and electrocardiogram confirmation was not available. Prior arrhythmias. Information on prior arrhythmias was collected in two ways. Investigators were asked to complete a "medical history" form at the screening visit. This form sought information on prior or ongoing problems. Investigators were also asked to complete a "signs and symptoms" baseline visit form at the time of randomization, designed to identify any changes in the patients' clinical condition from screening. The baseline visit usually occurred on the same date as screening, but could take place later. Because Ͼ5% of patients have a previous or ongoing atrial arrhythmia recorded at their screening visit, two sets of analyses were performed. The main analysis used all randomized patients. A separate analysis was carried out in the subset of patients without a history of atrial arrhythmias. A similar secondary analysis was performed for patients with prior or recent ventricular arrhythmias. Combined outcomes. To take account of the issue of "competing risks," in relation to the different survival rates in the two treatment groups (whereby deceased patients cannot be at risk of an arrhythmia), we also examined a number of combined outcomes, taking account of death or an arrhythmia. Statistical analysis. All analyses were carried out on an intention-to-treat basis. All outcomes were analyzed using a time-to-first-event approach. The statistical significance of treatment comparisons was based on the log-rank test. Hazard ratios (HR) and 95% confidence intervals (CIs) were derived from the fitting of Cox proportional hazards regression models with treatment assignment as the only factor. Cumulative incidence curves, which adjust for competing risks for censoring due to all-cause mortality, were used to show the accrual of events with time in the two treatment groups (24). The distribution of age at baseline is presented as mean and the range and categorical baseline characteristics are shown as percentages.
RESULTS
The baseline characteristics of the patients randomized in CAPRICORN are shown in Table 1 . A total of 9% of patients (89 placebo group, 81 carvedilol group) were recorded as having a prior or ongoing history of AF/atrial flutter, and 1.1% were identified as having had ventricular tachycardia (2 placebo group, 0 carvedilol group) or fibrillation (14 placebo group, 6 carvedilol group).
A total of 96 patients (5%) were treated with an antiarrhythmic drug at the time of randomization, and, in 95 of these 96, the treatment used was amiodarone (59 placebo group, 36 carvedilol group). (Fig. 2) . Among carvediloltreated patients, there were 4 episodes of ventricular fibrillation/flutter, 6 of ventricular tachycardia, and 19 of other ventricular arrhythmias (premature beats, couplets, and so on).
In the placebo group, these numbers were 17, 27, and 38, respectively. After excluding patients with a history of ventricular fibrillation/tachycardia, 25 of 969 (2.6%) carvedilol-treated patients and 66 of 968 (6.8%) placebo-treated patients had a report of a ventricular arrhythmia after randomization: HR 0.37 (95% CI 0.23 to 0.59; p Ͻ 0.0001).
"MALIGNANT" VENTRICULAR ARRHYTHMIAS. The comparable rates of ventricular tachycardia, ventricular fibrillation, or ventricular flutter were 9 of 975 (0.9%) in the carvedilol group and 38 of 984 (3.9%) in the placebo group, representing an HR of 0.24 (95% CI 0.11 to 0.49; p Ͻ 0.0001). Combined outcomes. Table 2 shows the combined outcomes of death or an arrhythmia. Carvedilol reduced the risk of all combined outcomes analyzed, including the outcome of death or any reported arrhythmia.
Arrhythmias and sudden death. Table 3 shows the relationship between arrhythmias and death from any cause and those adjudicated as sudden. Patients who experienced an arrhythmia were more likely to die and to have their mode of death classified as "sudden." There was a nonsignificant trend for fewer sudden deaths in the carvedilol group, especially in patients with an arrhythmia.
DISCUSSION
In this retrospective, but blinded, analysis of the CAPRI-CORN trial, carvedilol was shown to have a striking effect, not only on the incidence of ventricular arrhythmias but also on the risk of atrial arrhythmias.
The occurrence of AF after MI is associated with a worse clinical outcome, including a higher mortality (2-4,14 -17) . This is the case generally and also in patients with significant left ventricular systolic dysfunction after infarction. For example, the Trandolapril Cardiac Evaluation (TRACE) investigators found that AF was an independent predictor of both a higher in-hospital and long-term mortality (4). In the TRACE study, the risk of developing AF, over a mean follow-up of 2.2 years, was reduced in the ACE inhibitor group (n ϭ 22, 2.8%) compared with the placebo group (n ϭ 42, 5.3%) (21) .
Whether beta-blockers reduce the risk of atrial arrhythmias after MI has not been tested in a double-blind prospective, randomized, placebo-controlled trial, particularly in patients already treated with an ACE inhibitor. This analysis of the CAPRICORN trial suggests that carvedilol markedly suppresses atrial arrhythmias in these patients. It is of interest to compare these findings with the recent Danish Investigations of Arrhythmia and Mortality on Dofetilide-Myocardial Infarction (DIAMOND-MI) study, which examined the effect of a new class III antiarrhythmic agent in similar patients with those enrolled in the TRACE and CAPRICORN trials (25) . In the DIAMOND-MI study 58% of patients were treated with an ACE inhibitor and 36% with a beta-blocker at the time of randomization (25) . The risk of developing AF or atrial flutter, over a mean follow-up of 1.25 years, in patients in sinus rhythm at baseline was 14 of 705 (2.0%) in the placebo group The effect of beta-blockers on ventricular arrhythmias in the post-MI setting is more clearly established. Both substudies of the large beta-blocker secondary prevention trials and independent studies showed significant reductions in all grades of ventricular arrhythmias with propranolol, timolol, and metoprolol (9 -13,26 -29) . None of these studies, however, focused on patients with substantial left ventricular systolic dysfunction; indeed, it seems that high-risk patients were excluded from these studies (22, 23) . Furthermore, these studies were conducted before the benefits of ACE inhibitors, one of which is to reduce ventricular arrhythmias, had been established (19, 30, 31) . We were able to confirm that carvedilol reduced ventricular arrhythmias, even in high-risk patients treated with an ACE inhibitor. Indeed, the magnitude of this effect, be it on all ventricular arrhythmias or just "malignant" arrhythmias, was striking; the latter were reduced by 70%. Whether the size of this effect reflects just the beta-blocking action of carvedilol or an additional antiarrhythmic action of the molecule (for example, carvedilol has been shown, in vitro, to block HERG potassium channels) cannot be determined from the current study (32, 33) .
That the substantial reduction in "malignant" ventricular arrhythmias did not translate into a clearly significant reduction in sudden death (placebo 69 of 984 [7%], carvedilol 51 of 975 [5%]; p ϭ 0.098), as reported in the main CAPRICORN trial results paper (23) , might, at first sight, seem surprising. However, with only 120 sudden deaths in total, we had low statistical power to detect such a treatment effect. Furthermore, any such treatment effect might have been diluted by nonarrhythmic causes of sudden death such as bradycardia/asystole, pulmonary embolism, reinfarction leading to catastrophic pump failure, stroke, and other noncoronary vascular events (e.g., aortic aneurysm rupture) the risk of which may not be reduced by beta-blockade (34) . The use of amiodarone in a small proportion of patients might have similarly reduced our ability to show a difference between carvedilol and placebo. Furthermore, further analysis of mode of death in those experiencing an arrhythmia showed a strong trend to fewer sudden deaths in the carvedilol group.
The present analysis has a number of limitations. First, it was not prespecified. Second, it is based on an examination of AEs and SAEs without electrocardiographic validation of arrhythmias. Spontaneous AE and SAE reporting might be expected to underestimate the true incidence of arrhythmias. Comparison with other recent studies (e.g., the TRACE and DIAMOND studies), however, suggests that this is not the case for supraventricular arrhythmias (i.e., our rates of arrhythmias were similar to the rates reported in those other trials). We also believe that under-or overreporting of clinically important ventricular arrhythmias is unlikely. The recent Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy Survival Study (EPHESUS) is useful for comparison. Over an average follow-up of 1.33 years, 54 of 3,313 (1.6%) of placebo-treated patients (75% of whom were treated with a beta-blocker) were hospitalized for a ventricular arrhythmia. In the carvedilol group in the CAPRICORN trial, 9 of 975 (0.9%) of patients experienced a "malignant" ventricular arrhythmia over 1.3 years compared with 38 of 984 (3.9%) in the placebo group.
However, spontaneous reporting might exaggerate the apparent antiarrhythmic effect of carvedilol because this drug is likely to reduce awareness of an arrhythmia. What are the clinical implications of these findings? We believe that they reinforce the value of beta-blockers as essential treatment in patients with acute infarction (35) . Though other treatments (i.e., an implantable cardioverter defibrillator [36] and eplerenone [37] ) reduce the risk of sudden death (and death from any cause) in patients already taking a beta-blocker, carvedilol also reduces the risk of reinfarction (as do other beta-blockers) and of atrial arrhythmias.
In summary, in this nonprespecified analysis, carvedilol appeared to reduce the incidence of investigator-reported (but nonadjudicated) atrial and ventricular arrhythmias in patients with acute MI and associated impairment of left ventricular systolic dysfunction. This antiarrhythmic effect is additional to that known to be exerted by ACE inhibitors in these patients.
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